Eliza Slawther
Senior Writer
Eliza began reporting on health and medical science in 2018 while completing her Master’s degree in Journalism at City, University of London. During her degree program she interned at C+D and on the London Evening Standard’s health desk. In the years since, Eliza has written about everything from mid-stage drug development to market access for medicines and devices in the EU and beyond. Her work explores the trials and tribulations of securing reimbursement for medical products in Europe, and Eliza is particularly interested in the challenges of funding innovation in health care.
Eliza has lived in London since 2017 and is originally from Cheshire, in the north west of England. She has a BA in English Literature from the University of Manchester and is in the process of completing a second undergraduate degree in Biomedicine from Birkbeck College, an evening university that is part of the University of London.
Latest From Eliza Slawther
EU MDR Notified Bodies Reach 38 After Another Designation
Germany’s SZUTEST is the latest notified body to be designated under the EU Medical Device Regulation, bringing the total number to 38.
News We’re Watching – FDA Mammography Update, SVB Collapse, Zoll's Data Breach, And More
News we are keeping an eye on this week includes the FDA’s first traditional market authorization for a COVID-19 test and its approval of a new neurological diagnostic. The agency also updated its device shortage list and revised mammography guidelines.
Could A Robot Be Used To Grow New Human Cells? The UK Regulator Thinks So
Stem cell therapies have the potential to treat a vast range of conditions, from forms of blindness to Parkinson’s disease, but manufacturing these products is difficult. The UK medtech regulator is exploring whether a robot could solve this problem.
The EU NIS 2 Directive Is Here. What Does It Mean For Medtech?
The EU Network and Information Security (NIS) Directive 2 entered into force this year, replacing the original NIS Directive. Cybersecurity is at the heart of NIS 2, and some of the new provisions are particularly important for the medtech and health sector.
UK’s NHS Launches AI Regulation Service Specifically For Medtech Firms
The regulatory landscape for digital and AI-based products can be tough for companies and users alike to navigate. Four UK organizations have partnered up to create a service that aims to demystify complex regulatory rules around AI and digital medtech.
France Latest Country To Introduce Digital Medtech Reimbursement Fast-Track
France has introduced a fast-track market access pathway for certain digital health products, adding to similar schemes in neighboring EU countries Germany and Belgium. But how does the new reimbursement program work, and which products are eligible for coverage?